Latest news

• Novavax’s COVID-19 vaccine candidate approved by MHRA for adolescents aged 12 to 17

  In the paediatric expansion, Nuvaxovid achieved its primary immunogenicity endpoint and demonstrated 80% clinical efficacy overall at a time when the Delta variant was the predominant strain in the US.

• ONS data reveals significant decrease in COVID-19 antibodies

  Despite the decline, the UK has retained a baseline antibody level of at least 179ng/ml, determined at the height of the Delta variant. ... in response to the spread of the Omicron variant.

• UK study reveals Omicron variant ‘substantially less likely’ to cause long Covid

  variant from reports for the ZOE Health Study with what they had already discovered on the Delta variant. ... Researchers compared these cases to 41, 381 cases of adults who first tested positive between 1 June 2021 and 27 November 2021, when the Delta

• Will that be cash or charge?

  During the spring of 2021, the world watched in horror as the delta variant overwhelmed India.

• Sanofi/GSK vaccine boosts immune response

  Roger Connor, president of GSK Vaccines, added: “As the pandemic threat continues with the current dominant Delta variant and Omicron rapidly gaining ground, booster vaccines will continue to be needed to ... The 10, 000 participants will receive two